ARVN250516C10000
- 0.03
- -0.02-40.00%
Arvinas Newsroom
Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Cuts Target Price to $11
Arvinas Price Target Cut to $11.00/Share From $12.00 by Morgan Stanley
Arvinas Is Maintained at Equal-Weight by Morgan Stanley
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN)
New Analyst Forecast: $ARVN Given $16.0 Price Target
Citigroup Maintains Neutral on Arvinas, Lowers Price Target to $9.5
Arvinas Analyst Ratings
BMO Capital Maintains Outperform on Arvinas, Lowers Price Target to $10
Truist Downgrades Arvinas to Hold From Buy, Cuts Price Target to $11 From $21
Strategic Reprioritization and Future Potential Drive Buy Rating for Arvinas Holding Company
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Design Therapeutics (DSGN) and Arvinas Holding Company (ARVN)
Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $10 to $24
Arvinas Earnings Call: Clinical Progress and Strategic Shifts
Arvinas Is Maintained at Overweight by Wells Fargo
Arvinas Price Target Cut to $19.00/Share From $26.00 by Wells Fargo
Arvinas Price Target Cut to $8.00/Share From $12.00 by Goldman Sachs
Arvinas Is Maintained at Neutral by Goldman Sachs
Arvinas Price Target Cut to $16.00/Share From $32.00 by Guggenheim